Research into targeted therapies for IgA nephropathy is ongoing, with multiple companies actively developing treatments. The development of new therapies may lead to growth in related markets, such as the nephrotic syndrome and glomerulonephritis markets. The field is evolving, with emerging diagnostic approaches, updated treatment guidelines, and a growing number of companies involved in clinical trials for related conditions.